Target intelligence / Profile preview

Casein kinase 1 gamma-3 (CSNK1G3)

Target
CSNK1G3
Molecular classification
Enzyme, Serine/threonine protein kinase, Protein kinase (Casein kinase 1 family)
01

Overview

Casein kinase 1 gamma-3 (CSNK1G3) is a member of the CK1 family of serine/threonine protein kinases, characterized by its ability to phosphorylate casein and many acidic proteins[1][4][6]. It is encoded by the CSNK1G3 gene on human chromosome 5q23.2 and functions in diverse cellular processes, including cytokinesis, DNA repair, nuclear localization, protein transport, and especially key roles in **Wnt signaling**, where it phosphorylates the co-receptor LRP6 to promote pathway activation[1][4][7]. CSNK1G3 is widely expressed and implicated in the regulation of fast synaptic transmission via glutamate and potentially other neural processes[1]. Disease links include cancer, sarcosinemia, and specific brain development disorders, though clinical targeting remains investigational[1][5][7].

Other names
CKI-gamma 3CK1-gamma 3CSNK1G3LCasein kinase I isoform gamma-3Casein kinase I gamma 3
02

Mechanism of action

Inhibition of kinase activity (serine/threonine phosphorylation)[6]. Modulation of Wnt signaling by phosphorylation of pathway components[7][4].

03

Biological functions

Signal transductionWnt signalingFast synaptic transmission (via glutamate)DNA repairCell divisionProtein phosphorylationMembrane transportNuclear localizationRegulation of gene expression
04

Disease associations

CancerSarcosinemiaLissencephaly 8Possibly other developmental and neurodegenerative disorders
05

Safety considerations

Potential for broad effects on cell cycle, cell viability, and nervous system development due to widespread involvement in key signaling pathways.Risk for off-target effects because of homology with other CK1 family members and other kinases.
06

Interacting drugs

Data on specific small molecule inhibitors for CSNK1G3 is limited; several general CK1 inhibitors (not isoform-specific) exist in preclinical research but none are approved for clinical use specifically targeting CSNK1G3[6].
07

Biomarkers

No widely established CSNK1G3-specific biomarkers for patient selection or efficacy monitoring; potential for use as a research biomarker in Wnt-related cancers or developmental pathologies under investigation[5].

Beyond the preview

Go deeper on Casein kinase 1 gamma-3 (CSNK1G3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Casein kinase 1 gamma-3 (CSNK1G3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call